Della-Torre E, Campochiaro C, Cavalli G, et al. - Via this open-label study, researchers examined whether interleukin (IL)−6 blockade with sarilumab is safe and efficacious in patients with severe COVID-19 pneumonia and systemic hyperinflammation. Sarilumab 400 mg was administered intravenously in addition to standard of care to 28 patients and standard of care alone to 28 contemporary matched patients.  At day 28, no significant differences in terms of overall clinical improvement and mortality in patients with severe COVID-19, were observed between sarilumab and standard of care. A subset of patients showing minor lung consolidation at baseline had faster recovery in correlation with receiving sarilumab.